Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00050206 · ClinicalTrials.gov registry record · Phase 4
Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 130
- Enrollment target
NCT00050206 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 130 participants.
The verdict
NCT00050206, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 130 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the efficacy (how well the drug works), safety, and any side effects of olanzapine compared to placebo in the treatment of mania in bipolar disorder in adolescents. Both the potential benefits and side effects of olanzapine will be evaluated throughout this trial.
Interventions
- DRUG Placebo
- DRUG Olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2002-11 |
| Est. Completion | 2005-05 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00050206
The ClinicalTrials.gov registry entry for NCT00050206 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00050206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00050206 about?
NCT00050206 is a clinical study titled "Olanzapine Versus Placebo in the Treatment of Mania in Adolescents With Bipolar I Disorder". The purpose of this study is to determine the efficacy (how well the drug works), safety, and any side effects of olanzapine compared to placebo in the treatment of mania in bipolar disorder in adolescents. Both the potential benefits and side effects of olanzapine will be evaluated throughout this ...
What is the current status of trial NCT00050206?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 130 participants. The study started on 2002-11. Estimated completion is 2005-05.
What interventions are being tested in trial NCT00050206?
The interventions under investigation include: Placebo (DRUG), Olanzapine (DRUG).
Who is sponsoring clinical trial NCT00050206?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.